Somehow Washington regards the industry, which has saved and improved tens of millions of lives, as a villain.

The Board of Directors of Pharma Equity Group A/S has today considered and approved the Company's annual report for 2024, which can be summarised as follows: It is expected that the trial application ...

Servier announces a strategic worldwide licensing agreement for Black Diamond Therapeutics' BDTX-4933 for solid tumors for an ...

Jacobio Pharma (1167.HK) released its 2024 annual results, with revenue of RMB160 million, R&D expense of RMB330 million. Major operating and financing activities generated RMB320 million cash inflows ...

Among the 13 CAR-T therapeutics that have received regulatory approval are Gilead’s Yescarta and Immuneel Therapeutics’ ...

Based upon a successful engagement with the US Food and Drug Administration (FDA) at the End-of-Phase 2 meeting in January ...

After bringing Zolgensma to market in 2019 as the first gene therapy for spinal muscular atrophy, Novartis is back with a ...

This groundbreaking finding suggests that Telomir-1 may selectively benefit healthy cells while suppressing malignant growth, challenging the assumption that telomere-elongating drugs inherently ...

The Organ-on-a-Chip (OOAC) technology simulates various organ systems depending on the specific cell types seeded onto the ...

Jacobio Pharmaceuticals Group Co., Ltd. ( ($HK:1167) ) has issued an announcement. Jacobio Pharmaceuticals has announced significant progress in ...

New active ingredients such as antibodies are usually tested individually in laboratory animals. Researchers have now developed a technology that can be used to test around 25 antibodies ...